Skip to main content
SpringerLink
Log in

Moxifloxacin 0.5% Ophthalmic Solution

In Bacterial Conjunctivitis

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The fourth-generation 8-methoxyfluoroquinolone moxifloxacin is available as an 0.5% ophthalmic solution for use in the treatment of bacterial conjunctivitis.

Moxifloxacin had good activity against various Gram-positive and -negative ocular isolates in vitro, and moxifloxacin 0.5% ophthalmic solution achieved good penetration into ocular tissues in healthy volunteers and patients undergoing ocular surgery.

The efficacy of moxifloxacin 0.5% ophthalmic solution in the treatment of bacterial conjunctivitis has been shown in three randomized, double-blind, multicentre trials.

In a trial in patients aged ≥1 year, the clinical success rate was significantly higher with moxifloxacin 0.5% ophthalmic solution than with placebo. In a trial in patients aged ≥12 years, moxifloxacin 0.5% ophthalmic solution was noninferior to levofloxacin 0.5% ophthalmic solution in terms of the clinical success rate. In a third trial, the clinical cure rate was significantly higher with moxifloxacin 0.5% ophthalmic solution than with trimethoprim 1.0%/ polymixin B 10 000 IU/mL ophthalmic solution in paediatric patients aged ≤18 years.

Moxifloxacin 0.5% ophthalmic solution was well tolerated in patients with bacterial conjunctivitis. Ocular adverse events (e.g. eye pain, eye irritation) were the most commonly reported treatment-related adverse events, with the majority being of mild severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I.
Table II

Similar content being viewed by others

References

  1. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008 Feb; 86(1): 5–17

    Article  PubMed  Google Scholar 

  2. Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 2007 Aug; 8(12): 1903–21

    Article  PubMed  CAS  Google Scholar 

  3. Lichtenstein SJ, Dorfman M, Kennedy R, et al. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 2006 Jan/Feb; 43(1): 19–26

    PubMed  Google Scholar 

  4. Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of State Departments of Health. J Pediatr Ophthalmol Strabismus 2007 Mar/Apr; 44(2): 101–5

    PubMed  Google Scholar 

  5. Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. Epub 2010 Jun 8

  6. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med 2008 Jul; 75(7): 507–12

    Article  PubMed  Google Scholar 

  7. Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol 2005 Nov; 50 (6 Suppl. 1): S16–31

    Article  PubMed  Google Scholar 

  8. Pestova E, Millichap JJ, Noskin GA, et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000 May; 45(5): 583–90

    Article  PubMed  CAS  Google Scholar 

  9. Vigamox 5mg/ml eye drops, solution: EU summary of product characteristics. Hünenberg, Switzerland: Alcon, 2009

  10. Sosa AB, Epstein SP, Asbell PA. Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells. Cornea 2008 Sep; 27(8): 930–4

    Article  PubMed  Google Scholar 

  11. Donaldson KE, Marangon FB, Schatz L, et al. The effect of moxifloxacin on the normal human cornea. Curr Med Res Opin 2006 Oct; 22(10): 2073–80

    Article  PubMed  CAS  Google Scholar 

  12. Sueke H, Kaye S, Neal T, et al. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis. Invest Ophthalmol Vis Sci 2010 May; 51(5): 2519–24

    Article  PubMed  Google Scholar 

  13. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008 Jun; 145(6): 951–8

    Article  PubMed  Google Scholar 

  14. Ohnsman C, Ritterband D, O’Brien T, et al. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr Med Res Opin 2007 Sep; 23(9): 2241–9

    Article  PubMed  CAS  Google Scholar 

  15. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009 Aug; 53(8): 3552–60

    Article  PubMed  CAS  Google Scholar 

  16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 7th ed. Wayne (PA): Clinical and Laboratory Standards Institute, 2006: M7–A7

    Google Scholar 

  17. British Society for Antimicrobial Chemotherapy. BSAC methods for antimicrobial susceptibility testing [online]. Available from URL: http://www.bsac.org.uk/_db/_documents/Version_9.1_March_2010_final.pdf [Accessed 2010 Jul 2]

  18. Wagner RS, Granet DB, Lichtenstein SJ, et al. Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin. Clin Ophthalmol 2010; 4: 41–5

    PubMed  Google Scholar 

  19. Lichtenstein SJ, Wagner RS, Jamison T, et al. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv Ther 2007 Sep/Oct; 24(5): 1098–111

    Article  PubMed  CAS  Google Scholar 

  20. D’Arienzo PA, Wagner RS, Jamison T, et al. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant Gram-positive conjunctival pathogens. Adv Ther 2010; 27(1): 1–9

    Article  Google Scholar 

  21. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmaco-dynamic characteristics. Pharmacotherapy 2000 Mar; 20(3): 245–56

    Article  PubMed  CAS  Google Scholar 

  22. Mason BL, Alfonso EC, Miller D. In-use study of potential bacterial contamination of ophthalmic moxifloxacin. J Cataract Refract Surg 2005 Sep; 31(9): 1773–6

    Article  PubMed  Google Scholar 

  23. Yamada M, Yoshida J, Hatou S, et al. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br J Ophthalmol 2008 Jun; 92(6): 848–51

    Article  PubMed  CAS  Google Scholar 

  24. Park SH, Lim J-A, Choi J-S, et al. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea 2009 Jan; 28(1): 68–72

    Article  PubMed  Google Scholar 

  25. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004 Mar; 49 Suppl. 2: S79–83

    Article  PubMed  Google Scholar 

  26. Marshall B, Cupp G, Foster K, et al. Moxifloxacin treatment of conjunctivitis: microbial effects beyond the eye [abstract no. C2-103 plus poster]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12–15; San Francisco (CA)

  27. McDermott M, Wheater M. In vitro comparison of the effects of clinically available ophthalmic solutions of gatifloxacin 0.3% and moxifloxacin 0.5% on human corneal and conjunctival epithelial cell adhesion and migration and on collagen type IV protein expression. Cornea 2006 Oct; 25 (9 Suppl. 2): S25–30

    Article  Google Scholar 

  28. Tsai T-H, Chen W-L, Hu F-R. Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells. Eye 2010 May; 24(5): 909–17

    Article  PubMed  CAS  Google Scholar 

  29. Kim S-Y, Lim J-A, Choi J-S, et al. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 2007 Jul; 26(6): 720–5

    Article  PubMed  Google Scholar 

  30. Price MO, Price Jr FW, Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J Cataract Refract Surg 2005 Nov; 31(11): 2137–41

    Article  PubMed  Google Scholar 

  31. Burka JM, Bower KS, Vanroekel RC, et al. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photo-refractive keratectomy. Am J Ophthalmol 2005 Jul; 140(1): 83–7

    Article  PubMed  CAS  Google Scholar 

  32. Yee RW, Setabutr P, Foltermann MO, et al. The effects of topical moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution on corneal healing after bilateral photorefractive keratectomy. Cornea 2006 Oct; 25 (9 Suppl. 2): S8–11

    Article  Google Scholar 

  33. Torkildsen G, Proksch JW, Shapiro A, et al. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin Ophthalmol 2010; 4: 331–41

    PubMed  CAS  Google Scholar 

  34. Torkildsen G, O’Brien TP. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Clin Ther 2008 Nov; 30(11): 2005–14

    Article  PubMed  CAS  Google Scholar 

  35. Wagner RS, Abelson MB, Shapiro A, et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol 2005 Sep; 123(9): 1282–3

    Article  PubMed  Google Scholar 

  36. Kim DH, Stark WJ, O’Brien TP, et al. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005 Nov; 112(11): 1992–6

    Article  PubMed  Google Scholar 

  37. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005 Mar; 112(3): 466–9

    Article  PubMed  Google Scholar 

  38. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005 Nov; 24(8): 955–8

    Article  PubMed  Google Scholar 

  39. McCulley JP, Caudle D, Aronowicz JD, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006 Jun; 113(6): 955–9

    Article  PubMed  CAS  Google Scholar 

  40. Holland EJ, Lane SS, Kim T, et al. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea 2008 Apr; 27(3): 314–9

    Article  PubMed  Google Scholar 

  41. Lai WW, Chu KO, Chan KP, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol 2007 Aug; 144(2): 315–8

    Article  PubMed  CAS  Google Scholar 

  42. Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005 Jan; 123(1): 39–44

    Article  PubMed  CAS  Google Scholar 

  43. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 2006; 26(2): 191–5

    Article  PubMed  Google Scholar 

  44. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005; 50 (6 Suppl. 1): S32–45

    Article  PubMed  Google Scholar 

  45. Gross RD, Lichtenstein SJ, Schlech BA, et al. Early clinical and microbiological responses in the treatment of bacterial conjunctivitis with moxifloxacin ophthalmic solution 0.5% (Vigamox™) using b.i.d. dosing. Today’s Ther Trends 2003; 21(2): 227–37

    Google Scholar 

  46. Granet DB, Dorfman M, Stroman D, et al. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus 2008 Nov/Dec; 45(6): 340–9

    Article  PubMed  Google Scholar 

  47. Shimomura Y, Ohashi Y, Matsumoto K, et al. Phase III comparative study of moxifloxacin ophthalmic solution in bacterial conjunctivitis (multi center, double masked study) [in Japanese]. Atarashii Ganka 2007; 24(10): 1381–94

    Google Scholar 

  48. Alcon, Inc. Vigamox® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as base [online]. Available from URL: http://ecatalog.alcon.com/pi/Vigamox_us_en.pdf [Accessed 2010 Jul 2]

Download references

Acknowledgments and Disclosures

The manuscript was reviewed by: M.B. Abelson, Ora, Inc., Andover, Massachusetts, USA; F.T. Fraunfelder, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA; P.Y. Robert, Service d’Ophtalmologie, CHU Dupuytren, Limoges, France.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M. Moxifloxacin 0.5% Ophthalmic Solution. Drugs 71, 89–99 (2011). https://doi.org/10.2165/11205840-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205840-000000000-00000

Keywords

Search

Navigation